Biden Jabs at Pharma Drug prices are falling, but the President needs a foil for inflation.

September 2021 Vol 12, No 9



By The WSJ Editorial Board

President Biden is worried inflation is undermining public support for his agenda so he’s rounding up the usual villains. On Thursday he lambasted drug makers for “jacking up prices.” These are the companies that have produced the vaccines and treatments that are saving the world from Covid-19.

“Right now, right here in America, we pay the highest prescription drug costs of any developed nation in the world,” Mr. Biden said in touting his plan for drug price controls. He’s right, but Americans also get access to more and better treatments sooner—as with the Covid vaccines.

Profits from successful drugs finance research and development into new treatments and many failures that lead to future discoveries. Pfizer’s profits from blockbuster drugs like Viagra have allowed it to invest in its mRNA research that became the platform for its vaccine, new first-line treatment for non-small lung cancer, and novel oral treatment for advanced prostate cancer.

Meanwhile, drug prices have been falling due to increased competition. Prescription drug prices have declined 2.6% over the past year while the consumer-price index rose 5.4%. Here’s something else Mr. Biden got wrong: Medicare already negotiates over prescription drug prices, which is the reason some consumers aren’t seeing the price cuts.

Private insurers that manage Medicare Part D plans demand rebates from drug makers to place their drugs on formularies. The insurers then use the rebates to reduce premiums for all beneficiaries. As a result, drug makers raise their list prices, so some beneficiaries with higher deductibles and coinsurance pay more out of pocket for some drugs.

But a recent study by IQVIA found that net prices after rebates for brand medicines declined 2.9% in 2020. On a per capita basis, real net spending on medicines in the U.S. has increased by only 0.5% annually over the past decade even as higher-cost treatments such as Gilead’s Sovaldi for hepatitis C have been approved.

When Mr. Biden talks about letting Medicare “negotiate” prices, he means he wants to eliminate the profits that create the incentive to innovate. Large pharmaceutical companies invested $91 billion last year in new treatments. Moderna is dumping profits from its Covid vaccine into expanding its manufacturing base and pipeline of 23 investigational vaccines and treatments. Innovation isn’t cheap, but the pandemic showed Americans that the benefits in lives saved are priceless.

Reprinted by permission of the Wall Street Journal, Copyright © 2021 Dow Jones & Company, Inc. All Rights Reserved Worldwide. License number 5130931119060.

Related Articles
A Different Kind of Hospital Conference
Frederick Greene, MD, FACS
January 2023 Vol 14, No 1
It was September 2019. My colleagues and I had been immersed in articles and presentations regarding the “financial toxicity” that was affecting a large cohort of our cancer patients.
Biden’s Cancer ‘Moonshot’ Contradiction
November 2022 Vol 13, No 11
His new price controls might have killed Amgen’s breakthrough drug for lung cancer
The Drug Pricing ‘Slippery Slope’ Rep. Peter Welch breaks the code on the Senate’s new price controls
August 2022 Vol 13, No 8
Rep. Peter Welch breaks the code on the Senate’s new price controls.
Last modified: August 10, 2023

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
    Profession or Role
    Primary Specialty or Disease State